,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2011-11-30 23:30:00,"Boston Scientific Corporation 's ( BSX ) Cardiac Rhythm Management ( CRM ) should record higher sales with the US Food and Drug Administration (FDA) approving Incepta, Energen and Punctua cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs).",0.12513963878154755,0.006566311232745647,0.8682940602302551,neutral,0.11857333034276962
1,2011-11-30 23:30:00,These devices are meant to treat heart failure and sudden cardiac death.,0.1066197007894516,0.007788460236042738,0.8855918645858765,neutral,0.09883124381303787
2,2011-11-30 23:30:00,"Though expected, the US approval comes even earlier than the company's original guidance of late 2011 or early 2012.",0.22275041043758392,0.026312850415706635,0.75093674659729,neutral,0.19643756747245789
3,2011-11-30 23:30:00,CE Mark approval for these defibrillators was received in the second quarter of 2011.,0.2803419232368469,0.006948002614080906,0.7127100229263306,neutral,0.2733939290046692
4,2011-11-30 23:30:00,"The company is confident of the ready adoption of these devices as they come with improved therapy options, advanced battery longevity and a DF4 universal connector system.",0.8667372465133667,0.011794619262218475,0.12146808207035065,positive,0.8549426198005676
5,2011-11-30 23:30:00,The company also announced an extended warranty for these devices in the US and many international countries of up to 10 years.,0.6883474588394165,0.010543095879256725,0.3011094629764557,positive,0.6778043508529663
6,2011-11-30 23:30:00,"The latest approval is all the more significant as declining sales of ICD's and drug eluting stents ( DES ), contributing more than 40% of total sales, have been a major area of concern.",0.019838234409689903,0.959385097026825,0.020776689052581787,negative,-0.9395468831062317
7,2011-11-30 23:30:00,"During the most recent quarter, worldwide ICD sales declined 11% year over year to $360 million (14% down at CER) with a 20% decline in the US sales to $225 million and a 7% rise in international sales (down 2% at CER) to $135 million.",0.016709627583622932,0.9745440483093262,0.008746317587792873,negative,-0.9578344225883484
8,2011-11-30 23:30:00,"The contraction in the US ICD market is because of several factors - pricing pressure, physician reaction to study results published by the Journal of the American Medical Association regarding evidence-based guidelines for ICD implants, US Department of Justice (DOJ) investigations into hospitals' ICD implant practices, the expansion of Medicare recovery audits and an ongoing physician alignment to hospitals.",0.042862653732299805,0.8625297546386719,0.09460762143135071,negative,-0.8196671009063721
9,2011-11-30 23:30:00,"Moreover, according to the company's assumptions, the US ICD market weakened further in July and August compared to the second quarter.",0.05691852793097496,0.9277003407478333,0.01538118813186884,negative,-0.8707818388938904
10,2011-11-30 23:30:00,"Although the situation improved marginally in September and early October, the company needs another couple of quarters to assess if the market has indeed stabilized.",0.8977686762809753,0.032057445496320724,0.07017382234334946,positive,0.8657112121582031
11,2011-11-30 23:30:00,A similar scenario is observed at other major ICD players namely St. Jude Medical ( STJ ) and Medtronic ( MDT ).,0.2161910980939865,0.010845797136425972,0.7729631662368774,neutral,0.2053453028202057
12,2011-11-30 23:30:00,"Recently, St. Jude Medical has received FDA approval for its much awaited Unify Quadra CRT-D and Quartet Left Ventricular Quadripolar Pacing Lead, shipment of which is expected to begin shortly.",0.9029852151870728,0.014279283583164215,0.08273548632860184,positive,0.8887059092521667
13,2011-11-30 23:30:00,Approval of the new devices is a huge breakthrough for both Boston Scientific and St. Jude Medical with the potential to turn around the ailing ICD business.,0.9129592180252075,0.016417991369962692,0.0706227719783783,positive,0.8965412378311157
14,2011-11-30 23:30:00,"Earlier this year, Medtronic had received approval for its next generation Protecta ICD, capable of partially offsetting pricing pressure.",0.9319360256195068,0.014146686531603336,0.053917329758405685,positive,0.9177893400192261
15,2011-11-30 23:30:00,"The approval of the new line of ICDs for Boston Scientific comes on the heel of US approval of Promus Element Plus stent last week, well ahead of the company's original expectation of a mid-2012 approval.",0.8723533153533936,0.022180598229169846,0.10546606034040451,positive,0.8501726984977722
16,2011-11-30 23:30:00,Promus Element now represents $200 million in additional annualized gross margin contribution from the US and Japan by 2012 end.,0.5259218811988831,0.011437698267400265,0.4626404047012329,positive,0.514484167098999
17,2011-11-30 23:30:00,"Besides, the next generation Ingenio family of pacemakers is slated for launch in the US and EMEA in the first half of 2012, subject to regulatory approvals.",0.2303503006696701,0.006764830555766821,0.7628848552703857,neutral,0.22358547151088715
18,2011-11-30 23:30:00,The string of recent and impending approvals is expected to support the company's growth in 2012 fired by new product launches.,0.935850977897644,0.014026356860995293,0.05012267082929611,positive,0.9218246340751648
19,2011-11-30 23:30:00,"We have a Neutral recommendation on Boston Scientific, in line with the short-term Zacks #3 Rank (Hold).",0.03731623664498329,0.5864125490188599,0.37627124786376953,negative,-0.5490962862968445
20,2011-11-30 23:30:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
